Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Releases Ampligen Pancreatic Cancer Investor Presentation

Neutral Impact 2 of 5 other Written later

AIM ImmunoTech furnished a new investor presentation, "The Ampligen Opportunity," and a November 5, 2026 press release describing the rationale for combining Ampligen with Revolution Medicines' daraxonrasib in pancreatic cancer. The filing reports no financial results and no new clinical data, and the company states the proposed combination remains investigational.

Key points

  • The Phase 2 DURIPANC topline results are expected in Q1 2027, with additional analyses anticipated in Q3 2027.
  • The DURIPANC Phase 1/2 study enrolled 28 patients and tests Ampligen with durvalumab (Imfinzi) in metastatic pancreatic cancer.
  • Ampligen is not approved by the U.S. Food and Drug Administration for pancreatic cancer, and the company says the combination's safety and efficacy have not been established.

The filing

CompanyAIM ImmunoTech Inc. (AIM)
Form8-K, current report
Filed with the SECNov 5, 2026, 9:14 AM ET
Accession number0001493152-26-050093

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.